Alterazioni del campo visivo in soggetti con epilessia in trattamento cronico con Vigabatrin

Translated title of the contribution: Automatic perimetry abnormalities in Vigabatrin chronically treated epileptic patients

A. Tartara, C. A. Galimberti, I. Sartori, M. Versino, L. Politini, R. Manni, E. Perucca

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Sixty epileptic patients chronically receiving GVG underwent to automatic perimetry and to flash electroretinogram (ERG) and visual evoked potentials (VEPs). All patients suffered from partial epilepsy. The mean GVG dose was 2887±871 mg/die (ranging from 1000 to 4000). The mean treatment duration was 56.6±43.5 months (ranging from 2 to 182). In 50 patients GVG was associated with other antiepileptic drugs (carbamazepine in 46 of them). One of them complained of visual symptoms. ERG was normal in all the subjects. The VF evaluation was normal in 13 and not reliable in 10 subjects. Thirty-seven subjects showed different kind of VF defects, which were explainable by a retinal/prechiasmatic lesion in 22 of them (17 subjects showed a binasal defect, 5 a concentric costriction). In these patients VEPs were normal in 17 subjects and showed a delayed latency in 4, a reduced amplitude in 1. The VF alterations occurred more frequently in the patients with a treatment duration longer than 18 months. Our data show that asymptomatic VF defects occur frequently in patients with partial epilepsy chronically receiving GVG. The relationship between the occurrence of VF defect and treatment duration suggest that GVG plays a pathophysiological role.

Original languageItalian
Pages (from-to)189-190
Number of pages2
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number106-107
Publication statusPublished - 1999

Fingerprint

Vigabatrin
Visual Field Tests
Partial Epilepsy
Visual Evoked Potentials
Carbamazepine
Anticonvulsants
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Alterazioni del campo visivo in soggetti con epilessia in trattamento cronico con Vigabatrin. / Tartara, A.; Galimberti, C. A.; Sartori, I.; Versino, M.; Politini, L.; Manni, R.; Perucca, E.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 106-107, 1999, p. 189-190.

Research output: Contribution to journalArticle

@article{5f928db51d4e4e77b271fb5a3c40c404,
title = "Alterazioni del campo visivo in soggetti con epilessia in trattamento cronico con Vigabatrin",
abstract = "Sixty epileptic patients chronically receiving GVG underwent to automatic perimetry and to flash electroretinogram (ERG) and visual evoked potentials (VEPs). All patients suffered from partial epilepsy. The mean GVG dose was 2887±871 mg/die (ranging from 1000 to 4000). The mean treatment duration was 56.6±43.5 months (ranging from 2 to 182). In 50 patients GVG was associated with other antiepileptic drugs (carbamazepine in 46 of them). One of them complained of visual symptoms. ERG was normal in all the subjects. The VF evaluation was normal in 13 and not reliable in 10 subjects. Thirty-seven subjects showed different kind of VF defects, which were explainable by a retinal/prechiasmatic lesion in 22 of them (17 subjects showed a binasal defect, 5 a concentric costriction). In these patients VEPs were normal in 17 subjects and showed a delayed latency in 4, a reduced amplitude in 1. The VF alterations occurred more frequently in the patients with a treatment duration longer than 18 months. Our data show that asymptomatic VF defects occur frequently in patients with partial epilepsy chronically receiving GVG. The relationship between the occurrence of VF defect and treatment duration suggest that GVG plays a pathophysiological role.",
keywords = "Epilepsy, Vigabatrin, Visual field defects",
author = "A. Tartara and Galimberti, {C. A.} and I. Sartori and M. Versino and L. Politini and R. Manni and E. Perucca",
year = "1999",
language = "Italian",
pages = "189--190",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "106-107",

}

TY - JOUR

T1 - Alterazioni del campo visivo in soggetti con epilessia in trattamento cronico con Vigabatrin

AU - Tartara, A.

AU - Galimberti, C. A.

AU - Sartori, I.

AU - Versino, M.

AU - Politini, L.

AU - Manni, R.

AU - Perucca, E.

PY - 1999

Y1 - 1999

N2 - Sixty epileptic patients chronically receiving GVG underwent to automatic perimetry and to flash electroretinogram (ERG) and visual evoked potentials (VEPs). All patients suffered from partial epilepsy. The mean GVG dose was 2887±871 mg/die (ranging from 1000 to 4000). The mean treatment duration was 56.6±43.5 months (ranging from 2 to 182). In 50 patients GVG was associated with other antiepileptic drugs (carbamazepine in 46 of them). One of them complained of visual symptoms. ERG was normal in all the subjects. The VF evaluation was normal in 13 and not reliable in 10 subjects. Thirty-seven subjects showed different kind of VF defects, which were explainable by a retinal/prechiasmatic lesion in 22 of them (17 subjects showed a binasal defect, 5 a concentric costriction). In these patients VEPs were normal in 17 subjects and showed a delayed latency in 4, a reduced amplitude in 1. The VF alterations occurred more frequently in the patients with a treatment duration longer than 18 months. Our data show that asymptomatic VF defects occur frequently in patients with partial epilepsy chronically receiving GVG. The relationship between the occurrence of VF defect and treatment duration suggest that GVG plays a pathophysiological role.

AB - Sixty epileptic patients chronically receiving GVG underwent to automatic perimetry and to flash electroretinogram (ERG) and visual evoked potentials (VEPs). All patients suffered from partial epilepsy. The mean GVG dose was 2887±871 mg/die (ranging from 1000 to 4000). The mean treatment duration was 56.6±43.5 months (ranging from 2 to 182). In 50 patients GVG was associated with other antiepileptic drugs (carbamazepine in 46 of them). One of them complained of visual symptoms. ERG was normal in all the subjects. The VF evaluation was normal in 13 and not reliable in 10 subjects. Thirty-seven subjects showed different kind of VF defects, which were explainable by a retinal/prechiasmatic lesion in 22 of them (17 subjects showed a binasal defect, 5 a concentric costriction). In these patients VEPs were normal in 17 subjects and showed a delayed latency in 4, a reduced amplitude in 1. The VF alterations occurred more frequently in the patients with a treatment duration longer than 18 months. Our data show that asymptomatic VF defects occur frequently in patients with partial epilepsy chronically receiving GVG. The relationship between the occurrence of VF defect and treatment duration suggest that GVG plays a pathophysiological role.

KW - Epilepsy

KW - Vigabatrin

KW - Visual field defects

UR - http://www.scopus.com/inward/record.url?scp=0033500187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033500187&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0033500187

SP - 189

EP - 190

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 106-107

ER -